Mivavotinib

DB16849InvestigationalSmall molecule

Mivavotinib: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase SYK
Curator reviewed
Formula / weight: C₁₇H₂₁FN₆O · 344.394 g/mol (avg)
Code names: CB-659 · TAK-659F · TAK-659 free base

Resolves to

Compound

Structure

InChIKeyMJHOMTRKVMKCNE-NWDGAFQWSA-NSMILESCN1C=C(C=N1)C1=C2C(=O)NCC2=C(F)C(N[C@@H]2CCCC[C@@H]2N)=N1

Targets

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mivavotinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.